Compare FIGS & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIGS | VKTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2021 | 2014 |
| Metric | FIGS | VKTX |
|---|---|---|
| Price | $19.76 | $26.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | $21.13 | ★ $95.32 |
| AVG Volume (30 Days) | 4.5M | ★ 4.6M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 850.00 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $419,591,000.00 | N/A |
| Revenue This Year | $20.59 | N/A |
| Revenue Next Year | $9.43 | N/A |
| P/E Ratio | $121.89 | ★ N/A |
| Revenue Growth | ★ 59.47 | N/A |
| 52 Week Low | $8.36 | $23.82 |
| 52 Week High | $22.46 | $43.15 |
| Indicator | FIGS | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 47.92 |
| Support Level | $13.37 | $26.47 |
| Resistance Level | N/A | $34.00 |
| Average True Range (ATR) | 1.10 | 1.58 |
| MACD | -0.24 | 0.37 |
| Stochastic Oscillator | 8.20 | 73.44 |
FIGS Inc is a healthcare apparel company. It designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other healthcare apparel. The company sells products mainly through its direct-to-consumer (DTC) digital platform, consisting of its website, mobile app, and B2B business (TEAMS). It also operates physical retail stores, which are called Community Hubs, providing a retail experience for healthcare professionals. The company generates maximum revenue from the sale of scrubwear products. Geographically, it derives maximum revenue from the United States, followed by the rest of the world.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.